Taking this into account and also considering recent results on bladder cancer highlighting the importance of UCF DNA integrity for early diagnosis [15], we investigated the ability of this marker to distinguish between prostate cancer patients and healthy individuals by analyzing UCF-DNA fragments longer than 250 bp in 3 regions is known to be frequently amplified in solid tumors, including prostate cancer: c-Myc (8q24.21), HER2 (17q12.1), and BCAS1 (20q13.2) [19–21]. The gene discussed is MYC; the disease is urinary bladder carcinoma.